Comparing the current results to its competitors, Larimar Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 8.15 %, recorded in the same quarter.
Larimar Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in the biopharmaceutical industry, which is characterized by intense competition to develop new technologies and proprietary therapies. It faces competition from larger pharmaceutical companies, specialty pharmaceutical companies, biotechnology firms, academic institutions, governmental agencies, and public and private research organizations. Specifically, the company competes with Biogen’s SKYCLARYS™ (omaveloxolone), approved by the FDA in February 2023 and by the European Commission in February 2024 for the treatment of Friedreich's ataxia (FA) in adults and adolescents aged 16 and older.
March 11, 2024
Friedreich s ataxia (FA) is a debilitating, progressive, and rare neurological disorder that primarily affects the nervous system and muscles. It is caused by a genetic mutation that leads to reduced levels of frataxin, a protein critical for mitochondrial function. Larimar Therapeutics, a clinical-stage biotechnology company, is at the forefront of developing a promising treatment option for FA with their novel protein replacement therapy, nomlabofusp (CTI-1601). In a recent development, Larimar has commenced a long-term open label extension (OLE) study to evaluate the safety and efficacy of nomlabofusp in patients with FA.Nomlabofusp - Addressing the Root Cause of Friedreich s Ataxia:Nomlabofusp has been s...
Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Lipocine Inc is a pharmaceutical company focused on developing oral drug delivery systems for hormone therapeutics. Their business model involves conducting research and development to create innovative products that address unmet medical needs in areas such as testosterone replacement therapy and hypogonadism. The company aims to commercialize these proprietary drug candidates and collaborate with industry partners to enhance their potential reach and impact.
Insmed Inc operates as a biopharmaceutical company focused on developing novel therapies for serious and rare diseases. The company's business model revolves around discovering, developing, and commercializing innovative therapies to address significant unmet medical needs. Insmed Inc's efforts primarily center around leveraging its expertise in biologics and advanced drug delivery technologies to improve the lives of patients with rare pulmonary diseases.
Sources:
Larimar Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Larimar Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
